Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A

5(62.5%)

Early Phase 1

1(12.5%)

Phase 1

1(12.5%)

Phase 2

1(12.5%)

8Total

N/A(5)

Early Phase 1(1)

Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07806045Early Phase 1Not Yet Recruiting

Nebulized UC-EVs for Recurrent or Refractory IMIDs With Lung Involvement

Role: collaborator

NCT07201233Not ApplicableNot Yet Recruiting

Clinical Study on the Safety and Efficacy of Umbilical Cord Blood Infusion in Treating Bone Marrow Suppression .

Role: lead

NCT06427642Not ApplicableRecruiting

Efficacy Evaluation of UCB-MNCs in the Treatment of Refractory Neonatal Diseases

Role: lead

NCT05794425Phase 1Recruiting

Clinical Study of UCB Combined With UC-MSCs in the Treatment of Bone Marrow Failure Disorders

Role: lead

NCT05999656Not ApplicableUnknown

Human Cord Blood Mononuclear Cells in the Treatment of Refractory Diabetic Foot

Role: collaborator

NCT04997590Not ApplicableUnknown

Clinical Study of Umbilical Cord Blood Mononuclear Cells (UCB-MNCs) in the Treatment of Traumatic Fracture Healing

Role: collaborator

NCT04882683Not ApplicableUnknown

Clinical Study of Cord Blood Mononuclear Cells on Treatment of Hormone-resistant or Hormone-dependent Ulcerative Colitis

Role: lead

NCT03529136Phase 2Unknown

Clinical Trial of Umbilical Cord Mesenchymal Stem Cell Transfusion in Decompensated Liver Cirrhosis

Role: lead

All 8 trials loaded